Ascertainment of samples included in the Australian GWAS dataset
The primary GWAS described in this paper includes data from 7, 197 Australian individuals from three cohorts (AAGC, Busselton, QIMR) which are described below. Clinical characteristics for these individuals are summarised in Table S1 . Family history (% yes, no, unknown) 0,0,100 0,0,100 -0,0,100
Smoker ever (% yes, no, unknown) 47.6,47.9,4.5 43.7,49.9,6.4 -45.4,49,5.5
Medication ever (% yes, no, unknown) 0,0,100 0,0,100 -0,0,100
Steroids ever (% yes, no, unknown) 0,0,100 0,0,100 -0,0,100
Hospital ever (%yes, no, unknown) 0,0,100 0,0,100 -0,0,100 Smoker ever (% yes, no, unknown) 4.7,5.4,89.9 0,0,100 -0.7,0.8,98.4
Medication ever (% yes, no, unknown) 6.5,3.6,89.9 0,0,100 -1,0.6,98.4
Steroids ever (% yes, no, unknown) 1,9,89.9 0,0,100 -0.2,1.4,98.4
Hospital ever (%yes, no, unknown) 0.5,0. a A total of 1,827 individuals provided no information about their asthma status and were included in the analysis as unselected controls to improve power ( Figure S2 ). Family history was defined by the presence of one or more firstdegree relatives with asthma. SPT=skin prick test.
Australian Asthma Genetics Consortium (AAGC) cohort (n=1,810) In 2010, the AAGC was formed to promote a more rapid progress towards the identification of the genetic risk factors for asthma. As part of the AAGC, 2,030 subjects from Australia were genotyped using the Illumina 610K array, of which 1,810 (89%) passed genotyping quality control (QC) filters (Table S2) , including 1,695 subjects with a lifetime physician diagnosis of asthma and 115 subjects without asthma. These individuals were ascertained and tested as part of five different studies which are summarised below: QIMR, TAHS, CAPS, MESCA and LIWA. 585  380  69  176  727  1937   Unrelated   b   573  372  68  172  707  1892   Sex check  573  371  67  171  695  1877   Phenotype check   c   571  371  53  170  645  1810   Asthmatics  565  371  52  122  585  1695   Non-asthmatics  6  0  1  48  60  115 a Ancestry outliers were identified through multi-dimensional scaling analysis of identity-by-state (IBS) allele sharing, including 988 samples from the eleven HapMap3 populations (see also Figure S1 ).
b Pairs of relatives were identified through the analysis of genome-wide identical-by-descent (IBD) allele sharing and one individual from each pair was dropped from the analysis. For case-control pairs, the control individual was dropped. For case-case and control-control pairs, we dropped an individual based on the following study priority order: QIMR>MESCA>LIWA>CAPS>TAHS. c Non-asthmatic individuals were removed from analysis if they reported a positive family history of disease.
(A) Queensland Institute of Medical Research studies (QIMR, n=571
). Samples were drawn from three studies conducted at QIMR. The first and most significant source of participants was the 1995-1998 Asthma and Allergy study, which is described in detail elsewhere (1) . Briefly, 3,073 subjects were recruited from 802 families that were registered on the Australian Twin Registry and had at least one twin that previously reported a history of wheezing in studies conducted at QIMR and by collaborators elsewhere in Australia. Participants completed a questionnaire that was designed to validate the diagnosis of asthma and to obtain data on respiratory symptoms, environmental exposures and family history of asthma. In addition, participants underwent clinical testing, including lung function and skin prick tests. For the present study, we selected one individual from each family that had available DNA and answered "Yes, told to me by a doctor" to the question "Have you ever had asthma?"; in families with multiple affected individuals, we selected the case with the highest asthma symptoms score (2) . In total, 444 asthmatics were selected from this study for genotyping. Second, we supplemented this dataset with 156 unrelated asthmatic individuals that answered "Yes" to the question "Has a doctor ever diagnosed you as suffering from asthma?" in a study of atopic dermatitis conducted recently. Most of these (88%) also reported having had eczema diagnosed by a doctor. Lastly, we also selected 13 nonasthmatic individuals that answered "No" to the question "Has a doctor ever diagnosed you as suffering from Asthma?" and reported no asthma symptoms (including wheezing and chest tightness) in the Brisbane Adolescent Twin Study (BATS), which is described elsewhere (3). Briefly, twins were recruited in the context of an ongoing study of melanoma risk factors including benign melanocytic naevi, sun exposure time and pigmentation related variables. Twins were enlisted by contacting the principals of primary schools (first 7 years of education) in the greater Brisbane area, media appeals and by word of mouth. It is estimated that approximately 50 percent of the eligible birth cohort were recruited into the study. Twins were examined at age 12 years, and siblings at the same occasion if under 20 years of age. At the same time, twins and their parents completed questionnaires measuring melanoma risk factors, but that also included general health questions, such as asthma. Twins were again examined at age 14 and 16. Thus, a total of 613 individuals that participated in three QIMR studies were selected for genotyping; after QC, 571 samples were available for analysis. (8) . A subgroup of these respondents, selected based on their participation in the previous follow-ups, samples of which were enriched for asthma, were invited to participate in a more detailed laboratory study. Of 2,373 invited for the laboratory study, 1,389 (58.5%) took part in a full laboratory visit, 354 (15%) completed a telephone questionnaire only, and 630 (26.5%) withdrew. In total, 419 participants with asthma and a DNA sample were selected for genotyping as part of the AAGC GWAS. Doctor diagnosed asthma-ever was defined as a positive response to the question "Have you ever had asthma?", followed by "Was this confirmed by a doctor?".
(B) Tasmanian Health Study (TAHS; n=371

(C) Childhood Asthma Prevention Study (CAPS; n=53).
Between September 1997 and November 1999, we recruited pregnant women whose unborn children were at increased risk of developing asthma because one or more parents or siblings had asthma or wheezing. We excluded those with a pet cat at home, strict vegetarians, women with a nonsingleton pregnancy, and infants born earlier than 36 weeks of gestation (9, 10) . We assessed their asthma status by clinical assessment at ages 18 months, 3, 5 and 8 years (10-13). Between 2001 and 2004 blood was collected for DNA extraction from all available subjects whose parents gave consent. Cases ascertained for this study were those for whom DNA was stored and who had a physician-diagnosis of asthma at age 8 years.
(D) Melbourne Epidemiological Study of Childhood Asthma (MESCA; n=170). In 1964, a community-based study was initiated in which a cohort of 410 children was selected from 30,000 7-year-old children in Melbourne, Australia (14) . The cohort was stratified to provide three groups of approximately equal size of children with a history of wheezing of varying frequency and a control group with no history of wheezing. Wheezing and asthmatic status were initially determined by parental response to a questionnaire and were subsequently confirmed by clinical examination. These children were surveyed again at age 10, at which time an additional 83 children from the same 1957 birth cohort were recruited to enrich the group with severe asthma (15) . The subjects were followed and reviewed at ages 14, 21, 28, 35 and 42 years (16, 17) . At each review, their atopic status was determined (18) and lung function parameters were measured. At the 42-year follow-up, blood was taken from each of the available 244 individuals for genotyping and total IgE measurements, including the 195 individuals that are part of this study. Informed consent was obtained from all subjects, and the study was approved by the ethics committee of the Royal Children"s Hospital, Melbourne.
(E) Lung Institute of Western Australia (LIWA; n=645). The LIWA cohort was recruited from patients and normal subjects resident in Perth, Western Australia. Asthma was defined as physician-diagnosed adult asthma (18 and over) and all had face to face clinical review. The non-asthmatic control subjects had no history of asthma as defined by medical staff interview. All participants were unrelated with self-reported European ancestry between 18 and 89 years of age. The control subjects were recruited by random mail-out using the telephone directory to generate random addresses and the asthma patients were similarly recruited but supplemented for the more severe patients through physician referrals. All subjects gave written informed consent and completed a comprehensive questionnaire which was used in the assessment of phenotype. Approximately 20ml of blood was obtained from each participant and lung function was assessed by spirometry. Assessment of atopic status was based on a positive skin prick reaction (weal diameter >3mm) to at least one of five common aeroallergens: cat, dog, house dust mite, mould mix (Alternaria tenuis, Aspergillus mix, Cladosporium, Penicillin mix) and grass pollen mix (Kentucky Blue, Orchard, Red Top, Timothy, Sweet Vernal, Meadow Fescue, Perennial Rye). The study protocol was approved by the Human Research Ethics Committee of the Sir Charles Gairdner Hospital. After QC, 645 samples from this cohort were available for analysis.
Busselton Health Study (n=1,230) This cohort has been described in detail previously (19) and was included in the Moffatt et al. (20) asthma GWAS. Briefly, residents of the town of Busselton in the southwest of Western Australia have been involved in a series of health surveys since 1966. The population is predominantly of European origin. In 1994/95 there was a follow-up study involving a subset of those who had attended any of the previous surveys. Cases of asthma were defined as those who reported physician-diagnosed asthma at any survey that they attended from 1966 to 1994 (answer "Yes" to "Has your doctor ever told you that you had asthma?"). Controls are those who have consistently answered "No" to "Has your doctor ever told you that you had asthma?" at all previous surveys that they have attended from 1996 to 1994. After QC a total of 1,230 unrelated subjects were available for analysis.
QIMR GWAS cohort (n=4,157) Between 2007 and 2009, a total of 15,259 DNA samples were genotyped with Illumina 370K or 610K arrays as part of six projects conducted by QIMR. This dataset, including QC checks, is described in detail in Medland et al. (21) . For this study, we selected a subset of 2,483 samples genotyped with the 610K array and 1,674 with the 370K array that were confirmed to be unrelated to the samples included in the AAGC cohort. Of the 2,483 genotyped with the 610K array (QIMR_610K dataset), (1) 387 had answered "Yes" to the question "Has a doctor ever diagnosed you as suffering from asthma?" in the QIMR Asthma (n=39) or BATS (n=348) studies described above; (2) 1,248 answered "No" or "Never" to the questions "How often have you had asthma?", "Have you ever had asthma?" or "Has a doctor ever diagnosed you as suffering from asthma?" in the Canberra (22) (n=53), Alcohol (23) (n=527), Alcohol Relatives (24) (n =132), Aged (25) (n=165) or BATS (n=371) studies; and (3) 848 provided no information about their asthma status and were included in the analysis as unselected controls to improve power ( Figure S2 ). Similarly, of the 1,674 selected samples genotyped with the 370K array (QIMR_370K dataset), (1) 28 answered "Yes, told to me by a doctor" to the question "Have you ever had asthma?" in the QIMR Asthma study; (2) 667 answered "No" or "Never" to the questions "How often have you had asthma?" or "Have you ever had asthma?"in the Canberra (n=60), Alcohol (n=491), Alcohol Relatives (n=26) or Aged (n=90) studies; and (3) 979 provided no information about their asthma status and were included in the analysis as unselected controls. Note that the partition of QIMR cases and controls between the AAGC GWAS cohort and this QIMR GWAS cohort is purely a function of whether the samples had been previously genotyped in the context of another study (QIMR GWAS) or not previously genotyped (AAGC GWAS).
Combined dataset Thus, across the four datasets (AAGC, Busselton, QIMR_610K and QIMR_370K), genotype data were available for 7,197 subjects, including 2,669 physician-diagnosed asthmatics and 4,528 controls. Amongst the asthmatic cases were 1,438 (54%) subjects with childhood onset asthma (defined by an age-of-onset at or before age 16), 697 (26%) subjects with later onset asthma (age-of-onset after the age of 16) and 534 (20%) with unknown age-of-onset. All subjects were confirmed to be unrelated and of European ancestry ( Figure S1 ) through the analysis of genome-wide allele sharing. This dataset includes 4,259 samples that have not been previously included in any asthma GWAS, 1,708 that were included in Ferreira et al. (26) and 1,230 samples from the Busselton cohort included in the GABRIEL study (20) . The y-axis represents the smallest detectable genotype relative risk (GRR) with 80% power (α = 5x10 -8 ) under a multiplicative model and assuming a disease prevalence of 10%. Two situations were considered. The first (green line below), which corresponds to the main analysis reported in the main text, represents the analysis of 2,669 asthma cases and 2,701 asthma-free plus 1,827 asthma-unknown controls. For comparison, we also show the smallest detectable GRR expected if the 1,827 individuals with an unknown asthma status were not included as controls in the analysis (red line above). For a higher disease prevalence (15% or 20%), the improvement in power by including the unselected controls is weaker (not shown).
Ascertainment of samples included in the follow-up phase
We carried out a replication study to validate in an independent panel of 25,358 individuals the association with seven SNPs identified with P ≤ 5x10 -6 in the main association analysis (n=2) or in the meta-analysis of results from our study and Moffatt et al. (20) (n=5). This panel included 3,322 asthmatic individuals and 22,036 controls ascertained and previously genotyped through four different studies (Raine, QIMR, NTR, APCAT) as described below. SNPs were tested in each study separately and then combined by performing a fixed-effects meta-analysis with METAL (27) .
Raine cohort (n=1,275) Recruitment of the Western Australian Pregnancy (Raine) cohort has previously been described in detail (28) (29) (30) . In brief, between 1989 and 1991, 2,900 pregnant women were recruited prior to 18-weeks gestation into a randomised controlled trial to evaluate the effects of repeated ultrasound in pregnancy. Children have been comprehensively phenotyped from birth to 21 years of age (average ages of one, two, three, six, eight, ten, fourteen, seventeen and twenty-one) by trained members the Raine research team. Data collection included questionnaires completed by the child"s primary carer and by the adolescent from age 14, physical assessments by trained assessors at all follow-up years, DNA collection from year 14 follow-up. Cases of asthma (n=654) are defined as subjects who answered "Yes" to the question "Has a doctor (GP, paediatrician, respiratory specialist) ever told you that your child has asthma?" at least once in year 5, year 8, year 10, year 14 and year 17 follow-ups. Controls (n=621) answered "No" to the same question across all available time points. Only individuals of European ancestry were included in the analysis. The study was conducted with appropriate institutional ethics approval, and written informed consent was obtained from all mothers. DNA samples were genotyped using Illumina 660 Quad arrays; the seven SNPs considered for follow-up passed strict quality control filters.
QIMR follow-up cohort (n=2,808) Amongst the 15,259 individuals previously genotyped by QIMR (see QIMR GWAS cohort above), there were 602 individuals with self-reported (but not physician-diagnosed) lifetime asthma that were not included in the Australian GWAS to ensure that results were based on a phenotype definition that matched that used by other asthma GWAS. However, we have previously noted that a lifetime asthma definition is highly correlated (0.99) with a lifetime physician-asthma definition (1) and that this self report is informative in mapping genuine asthma loci (26) . We therefore selected these 602 asthmatics for the replication phase, including 306 samples that were genotyped with the 610K array and 296 with the 370K array. Of those 306 genotyped with the 610K array, (1) 235 answered "Sometimes", "Only as a child", "Often" or "Quite often" to the question "How often have you had asthma?" in the Canberra (22) (n=12), Alcohol (23) (n=144) or Alcohol Relatives (24) (n=79) studies; and (2) 71 answered "Yes", "Now", "Past" or "Now and Past" to the question "Have you ever had asthma?" in the Asthma (1) (n=45) or Aged (25) (n=26) studies. Similarly, of the 296 individuals genotyped with the 370K array, (1) 257 answered "Sometimes", "Only as a child", "Often" or "Quite often" to the question "How often have you had asthma?" in the Canberra (n=9), Alcohol (n=184) or Alcohol Relatives (n=64) studies; and (2) 39 answered "Yes", "Now", "Past" or "Now and Past" to the question "Have you ever had asthma?" in the Asthma (n=28) or Aged (n=11) studies. The average age of participants (62% female) was 35 years (range 18-80); there was no additional clinical information available for these participants. Controls for this cohort were drawn from the same set of 15,259 genotyped individuals from QIMR. In this case, we selected 2,206 individuals (all females) that were genotyped with the 610K array as part of a GWAS for endometriosis (31) and that had not been included in our GWAS discovery phase. No asthma information was available for these individuals and so they constitute a group of unselected controls. All individuals were confirmed to be of European ancestry through genome-wide IBS analyses.
The Netherlands Twin Registry cohort (NTR; n=2,671) Data from two samples drawn from the NTR were included for analysis.
(A) NTR1 sample (n=1,612). Participants were drawn from the GAIN-MDD study, which is a case-control study of major depressive disorder in unrelated individuals. Average age of participants (65% female) was 43.8 years (SD = 13.6); participants gave informed consent to participation, and all studies were approved by appropriate ethics committees. Genotyping was conducted by Perlegen Sciences (Mountain View, CA, USA) with the use of a set of four proprietary, high-density oligonucleotide arrays. The SNP quality-control process is described in detail elsewhere (32) . A total of 427,303 autosomal SNPs passed QC criteria. We inferred unmeasured HapMap SNPs in each panel separately using MACH and the phased haplotype data from the CEU HapMap samples (phase I+II, release22, build 36) as reference. Following imputation, data for 2.5 million Hapmap SNPs were available; of these, we dropped SNPs with an imputation score < 0.3, MAF < 0.01 or with a Hardy-Weinberg equilibrium test with P < 10 -6 . Data were available for 205 and 1,407 individuals who respectively answered "Yes" and "No" to the question "Have you ever had asthma diagnosed by a doctor?". sample (n=1,059) . This sample was randomly drawn from the NTR-Biobank study (33) . We optimized the number of unrelated individuals who were genotyped. Average age of participants (61% female) was 49.2 years (SD = 14.0); participants gave informed consent to participation, and all studies were approved by appropriate ethics committees. Genome-wide SNP-genotyping was performed with Illumina 660W arrays; QC excluded SNPs based on MAF < 0.01, missing genotype rate > 0.05 or a P-value < 10 -5 in a test of Hardy-Weinberg equilibrium, leaving 515,781 SNPs available for analysis. Samples were excluded if they showed evidence for contamination by excessive allele sharing with multiple samples and excessive levels of heterozygosity (F < -0.10). Samples were also excluded if they had a higher than 90% genotype missing rate. Subsequently, genotypes of ~3.8 million SNPS were imputed with Impute (34), using the HapMap CEU data (release 24, NCBI build 36), available from the Impute website, as reference. Imputed SNPs were excluded if they had a minor allele frequency < 0.01 or a properinfo < 0.3, leaving 2,147,160 autosomal SNPs for analysis. Data were available for 145 and 914 individuals who respectively answered "Yes" and "No" to the question "Have you ever had asthma diagnosed by a doctor?". ). These studies are described in detail in the references provided in Table S3 and summarised below. Unmeasured HapMap SNPs were imputed with MACH. SNPs were tested for association with asthma using logistic regression and considering SNP additive effects. Age (H2000, Finrisk, Young Finns Study), sex and four ancestry-informative principal components were included as covariates. Three separate association analyses were conducted, corresponding to the following panels: (1) the Framingham Heart Study; (2) the NFBC66 study; and (3) the combined analysis of the HBC, H2000, Finrisk and Young Finns studies. Results from the three panels were then meta-analysed with METAL (27) . (H2000; n=1,994) . The protocol for this study is described in detail elsewhere (36) and included home interview, completion of several questionnaires, laboratory and anthropometrical measurements, spirometry with bronchodilator test and clinical examination by a physician. Further information was obtained by record linkage with the National Hospital Discharge Register and the National Social Insurance Institutions register data on reimbursement of asthma medication. Asthma diagnosis was based on all of the above mentioned data and confirmed by the physician. Samples were genotyped with Illumina 610K or 370K arrays, with 1,994 individuals included in this analysis.
(B) NTR2
Analysis in
Population-based Cohorts of Asthma Traits (APCAT; n=18,604) The APCAT consortium includes information for 1,716 physician-diagnosed asthmatics and 16,888 asthma-free controls (
(C) Finrisk study (n=1,865
). This study is a population survey of risk factors for chronic diseases in Finland (37) . The survey has been executed every five years from 1972 using independent, random and representative population samples from five geographical areas of the country. Participants have completed a health-related questionnaire and undergone a physical examination including measurement of anthropometric traits and blood draw. A total of 1,865 individuals with available physician-diagnosed asthma status were genotyped with Illumina 610K or Affymetrix 6.0 arrays.
(D) Northern Finland Birth Cohort 1966 (NFBC66; n=3,866).
The NFBC66 study is an on-going follow-up study of people whose expected date of birth was in 1966 in the provinces of Oulu and Lapland (38) . Primary clinical data collection on parents and the child occurred prenatally and at birth. Data collection on the child continued at several age points. At age 31, participants were sent a postal questionnaire and invited for clinical assessment where DNA was collected with informed consent. Information on asthma, hay fever and smoking used in this analysis was collected at this time point, with some incomplete information filled during clinical assessment. More details about this study can be found at http://kelo.oulu.fi/NFBC/. Genotyping was performed with Illumina Infinium for 339,629 SNPs. Young Finns Study (n=1,963) . The Young Finns cohort is a longitudinal population study sample on the evolution of cardiovascular risk factors from childhood to adulthood (39) . The first cross-sectional survey was conducted in 1980 in five Finnish university cities and included 3,596 participants who were in the age groups of 3, 6, 9, 12, 15, and 18 years and were randomly chosen from the national population register; equal ratios of males and females were selected in each age group. In 2007, 2,204 subjects now aged 30 to 45 years participated in the latest follow-up study. Of these, 1,963 individuals with available physician-diagnosed asthma status were genotyped with the Illumina 670K array.
(E) The
(F) Framingham Heart Study (FHS; n=7,260).
The FHS is a collection of cohorts recruited to investigate cardiovascular disease and its risk factors as described in detail elsewhere (40) . Asthma was classified based on selfreport of a physician"s diagnosis. Genotyping was performed using the Affymetrix 500K array and supplemented with the HuGeneFocused 50K array. a GenCall score not available in this cohort. b The AAGC dataset included predominantly (94%) asthmatic cases and so a MAF filter was only applied after merging this dataset with the QIMR_610K data. Furthermore, this over-representation of cases in one dataset could be a potential confounder for the analysis of SNPs whose genotype calling is affected by dataset-specific technical artefacts. To identify and remove such SNPs, we compared the allele frequency between AAGC cases (N=1,695) and QIMR_610K cases (N=397), as well as between AAGC controls (N=115) and QIMR_610K controls (N=1,267). The genomic inflation factor for these analyses was 1.001 and 1.014, respectively, indicating that there were no systematic allele frequency differences between the two datasets. We nonetheless removed a small subset of 1,104 SNPs (0.2%) that had significant (P < 0.001) allele frequency differences between the two datasets. MAF=minor allele frequency. QC=quality control. a Analyses were performed after excluding overlapping samples between this study and the GABRIEL (20) . b The association P-value corresponds to the fixed-effects meta-analysis conducted by the GABRIEL (20) . c Results for a test of heterogeneity (Breslow-Day test for the Australian GWAS; Cochran"s Q test for all other analyses). The table highlights: (1) in yellow, 12 SNPs located in regions reported to associate with asthma in previous GWAS (20, 41) ; (2) in blue, two SNPs with P>0.05 in the Australian GWAS and not reported to associate with asthma in previous GWAS; and (3) in green, five SNPs with P≤0.05 in the Australian GWAS and not reported to associate with asthma in previous GWAS -only these five SNPs were selected for follow-up. MAF=minor allele frequency. OR=odds ratio. k=number of analysis panels. Association results (-log 10 P-value, y-axis) are shown for genotyped (triangles) and imputed (diamonds, HapMap 3; circles, 1000 Genomes Project) SNPs located within 250 kb of rs4129267 and rs7130588 (blue triangles in each panel), and tested in 2,110 asthma cases and 3,857 controls from our study. The color of the remaining markers reflects the linkage disequilibrium (r 2 ) with rs4129267 or rs7130588 (increasing red hue associated with increasing r 2 ). Samples from the Busselton cohort that was included in the GABRIEL study (20) were excluded from this analysis. The recombination rate (second y-axis) is plotted in light blue and is based on the CEU HapMap population. Exons for each gene are represented by vertical bars. (20) . k=number of analysis panels. a Effect corresponds to the odds ratio for the minor allele for the four binary traits or the slope from a linear regression (beta) for the five continuous traits, the latter including age, sex, height, ever and current smoker as covariates. Eosinophil and total IgE levels were log transformed prior to the analysis. b Atopy was defined by a positive skin prick test to at least one common allergen. c Eczema was defined by a self-reported physician diagnosis of the disease. a For completeness, we also included the three loci reported by the GABRIEL consortium (20) that did not reach genome-wide significance in that study, namely RORA, SLC22A5 and IL13. b SNPs were directly genotyped in all cohorts with the exception of rs3771166 and rs2073643 (imputed in the QIMR_370K dataset only, information = 0.99 and 0.92, respectively), rs2284033 and rs9273349 (imputed in all cohorts, information = 0.84 and 0.98, respectively). Analyses were performed after excluding overlapping samples between this study and the GABRIEL (20) . OR=odds ratio. Ref=reference. Table S10 . e Significance of the best SNP after accounting for the number of, and LD between, SNPs tested in the respective gene, estimated from 10,000 permutations. LD=linkage disequilibrium. 
